Accueil > Actualité > Société

J&J: stop the study evaluating macitentan 75 mg

(CercleFinance.com) - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced its decision to stop the Phase 3 MACiTEPH study evaluating macitentan 75 mg in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) due to futility.


The decision to stop the trial was made in accordance with a recommendation by the study's independent data monitoring committee following a pre-planned interim analysis. No new safety signals were observed.

The interim results of MACiTEPH do not impact any of the Company's commercialized pulmonary hypertension medicines. Additionally, the pivotal Phase 3 UNISUS study, which aims to establish the superiority of a 75 mg dose of macitentan over the currently available 10 mg dose in patients with pulmonary arterial hypertension, is currently continuing as planned.

Copyright (c) 2023 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

Sondage

A quel niveau sera le CAC40 à fin décembre 2023:

En hausse à 7650Pts
En hausse à 7480Pts
Stable sur le niveau des 7230Pts
En baisse à 7100Pts
En baisse à 6850Pts
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.